Chickpea protein

Chickpea Protein (Cicer arietinum L.)

1. Identity: Botanical Classification, Nomenclature, and Natural Source

Cicer arietinum L., commonly known as the chickpea, is an annual plant of the family Fabaceae, mainly grown in semiarid and temperate regions. It is also known by numerous common names, including garbanzo bean, Bengal gram, Egyptian pea, and ceci bean. Chickpea, Cicer arietinum, is a high-protein legume. It is an ancient pulse crop and is the world's third most essential food legume, currently cultivated in over 13.7 million hectares, with an annual production of 14.3 million tons as of 2019.

Chickpea can be classified into two types based on its geographical distribution: Desi (originating in India) and Kabuli (originating in the Mediterranean). The surface of the Kabuli chickpea has a beige coat and it is a large seed without edges, while the Desi chickpea has a dark-colored coat over small and rough seeds. These two botanical subtypes differ meaningfully in protein content and antinutritional factor profiles. The protein content of the Kabuli chickpea (approximately 20.55%) is lower compared to the Desi type (approximately 29.2%) according to some studies. More generally, chickpea protein content varies significantly on a dry mass basis — from 17–22% before dehulling to 25–29% after dehulling.

1.1 Common Commercial Forms and Preparations

Chickpea protein is commercially available in several distinct forms with progressively increasing protein concentrations:

• Whole chickpea flour (besan/gram flour): Produced by grinding dried chickpeas, resulting in a product with protein content reflecting the raw seed (approximately 16–27%). The protein content of chickpeas is generally found to be 16–27%, depending on the variety and variations between harvest seasons.
• Chickpea protein concentrate (CPC): Produced by removing starch and other non-protein components, typically by wet or dry fractionation (air classification). Reported protein content of chickpea concentrates ranges from 63.9% to 89%, while commercial protein concentrates produced mainly by air classification range from 50% to 60% in protein.
• Chickpea protein isolate (CPI): Prepared from ground chickpea seeds by alkaline extraction and acid precipitation of the proteins at the isoelectric point (pI 4.3). These isolates can contain 78–88.1% protein and have a balanced content of essential amino acids with respect to the FAO reference pattern.
• Chickpea protein hydrolysate: Produced by enzymatic, acid, or alkaline hydrolysis of chickpea proteins to yield shorter peptides with various bioactivities. Peptides can be obtained through acid, alkali, and enzymatic hydrolysis, of which enzymatic hydrolysis is considered the safest approach; various enzymes used include flavorzyme, chymotrypsin, pepsin, alcalase, papain, and trypsin, either alone or in combinations.
• Aquafaba powder: A more recent preparation made by freeze-drying the cooking or soaking water from chickpeas, used primarily for its protein-based emulsifying and foaming properties.

Chickpea protein's versatility enables its use in various forms — such as isolates, concentrates, and textured proteins — contributing to the development of a diverse array of plant-based foods, including dairy alternatives, snacks, frozen desserts, nutritional supplements, and gluten-free products.

2. Traditional and Historical Use

2.1 Origins and Prehistoric Use

The chickpea was originally domesticated along with wheat, barley, peas, and lentils during the First Agricultural Revolution about 10,000 years ago. Chickpeas are believed to have originated within the Fertile Crescent, a region encompassing modern-day southeastern Turkey and adjoining Syria. Archaeological findings indicate that chickpea domestication began during the Pre-Pottery Neolithic period, approximately 11,000 years ago, with evidence from early cultivation sites including Tell el-Kerkh and Dja'de in Syria, and Çayönü and Hacilar in Turkey.

From their origin in the Fertile Crescent, chickpeas spread globally through ancient trade routes and human migrations; by approximately 5500 BC, they extended westward into modern Greece and other parts of Europe. Their presence is documented in the Nile Valley, with findings dating back to the New Kingdom period, around 1580–1100 BC; the legume reached the Indian subcontinent by around 2000 BC, becoming a deeply ingrained part of Indian cuisine.

2.2 Ancient Mediterranean and Near Eastern Use

Chickpeas were popular in ancient Egypt and Greece, where they were used in a variety of dishes including stews, salads, and desserts. They were also popular in ancient Rome, where they were used in porridges, soups, and salads, and were also ground into flour to make bread. Since ancient times, chickpeas have been a symbol of prosperity and good fortune, appearing in the celebrations and festive rites of various cultures. The ancient Romans associated the chickpea with Venus — the goddess of love — believing it increased the production of semen in men and milk in nursing mothers.

2.3 South Asian Culinary and Medicinal Traditions

In South Asian cuisine, chickpea flour (besan) is used as a batter to coat vegetables before deep frying to make pakoras. In India, chickpea flour, called besan or gram flour, is used to make besan chilla (spicy chickpea flour pancakes), besan ki roti (a flatbread), and various pakoras — savory vegetable fritters among India's most popular street foods. Chickpeas are one of the most popular vegetarian foods in the Indian subcontinent and in diaspora communities of many other countries, served with a variety of bread or steamed rice.

Traditional South Asian medicine (Ayurveda) and folk traditions used chickpeas as a dietary staple valued for sustaining energy and as a protein source, particularly important in vegetarian communities. Some legumes, including chickpea (Cicer arietinum), have been studied only in the context of their traditional use as an animal feed; however, interest in their high protein content for human consumption has increased significantly.

2.4 Middle Eastern Use

The Middle East is perhaps the region most closely associated with chickpeas. In countries such as Lebanon, Syria, and Jordan, chickpeas are a staple ingredient in many traditional dishes. One of the most famous is hummus, a creamy dip made from chickpeas, tahini, garlic, and lemon juice. Falafel — a crispy, flavorful street food made from chickpea patties — is another prominent Middle Eastern chickpea preparation.

2.5 Cultural and Ritual Significance

Ashkenazi Jews traditionally serve whole chickpeas, referred to as arbes in Yiddish, at the Shalom Zachar celebration for baby boys; the chickpeas are boiled until soft and served hot with salt and ground black pepper. Chickpea flour is also used to make "Burmese tofu," first known among the Shan people of Burma.

3. Key Constituents and Active Compounds

3.1 Protein Fractions

Globulins are soluble in salt solutions and constitute the most abundant group of chickpea proteins, being 55–60% of the total protein fraction. Globulins can be further distinguished by their sedimentation coefficient into three classes: legumins (11S; S = Svedberg Unit), vicilins (7S), and a third type present in minor amounts, known as convicilins. Legumins (11S) are the most abundant globulin components.

Chickpea globulins include 11S legumin (320–400 kDa) and 7S vicilin (145–190 kDa). Legumins are oligomeric proteins composed of six αβ subunits linked by disulfide bonds. Vicilins are trimeric proteins, and were traditionally described as lacking cysteine residues, although more recent analysis has found they do contain this amino acid residue.

Albumins represent about 8–14% of the total protein content and are the water-soluble components of the protein fraction. They are mainly enzymatic and metabolic proteins, with a high content of sulfur-rich amino acids, and are compact globular units ranging in molecular weight from 10 to 80 kDa.

The main proteins in chickpeas, on a proportional basis, are globulins (53–60%), glutenins (19–25%), albumins (8–12%), and prolamins (3–7%). Prolamines contain a high content of glutamine and proline and are soluble in alcohol. Cysteine and methionine concentrations are higher in gluteins, which are soluble in reducing salts, bases, acids, and detergents.

3.2 Amino Acid Profile

Chickpea varieties contain all essential amino acids except tryptophan in their profiles. Histidine is especially abundant in both varieties studied; in one variety (Costa 2004), aspartic acid and arginine are particularly prominent, while in another (El Patrón), threonine is the second most abundant after histidine. Chickpea protein isolates have a balanced content of essential amino acids with respect to the FAO reference pattern. Methionine and cysteine are typically the first limiting amino acids, a characteristic shared with most legumes.

3.3 Bioactive Peptides

For the production of chickpea hydrolysates and peptides, numerous methods have been applied that improve functional properties such as angiotensin I-converting enzyme (ACE) inhibitory activity, metal-chelating ability, antihyperlipidemic, antioxidant, antiproliferative, and antitumor activity.

Chickpea (Cicer arietinum L.) peptides have shown in vitro potential to inhibit the angiotensin I-converting enzyme (ACE-I). Legumin and provicilin sequences have been submitted to in silico analysis, and simulated enzymatic hydrolysis using the BIOPEP-UWM database identified 59 out of 381 peptides with ACE-I inhibitory potential. Legumin peptides showed better ACE-I inhibitory potential than the provicilin ones.

Food-derived bioactive peptides are typically 2 to 20 amino acid fragments from food proteins that exhibit specific types of biological activity depending on the amino acid sequence, length, and configuration. They may have regulatory functions in human systems that go beyond the nutritional value of the parental protein; in addition to lowering blood pressure, antioxidant, antimicrobial, immunomodulatory, cholesterol-lowering, and antidiabetic effects have also been reported.

3.4 Other Bioactive Constituents

Chickpeas demonstrate an antioxidant capacity ranging from 319 to 387 µMET/g and total phenol levels exceeding 500 mg/g. Phytic acid, lectins, sterols, saponins, dietary fibers, resistant starch, oligosaccharides, unsaturated fatty acids, amylase inhibitors, and certain bioactive compounds such as carotenoids and isoflavones have shown the capability of lowering clinical complications associated with various human diseases.

4. Scientific Evidence by Area of Use

4.1 Glycemic Control and Blood Sugar Regulation

Chickpea is rich in protein and has been demonstrated to possess hypoglycemic effects. At the cellular and enzymatic level, one bioactive peptide fraction (CBP-75-3) derived from chickpea protein was found to inhibit α-glucosidase (GAA) activity and significantly increase the viability of insulin-resistant (IR) cells, as well as significantly increase the rate of glucose consumption and glycogen synthesis in insulin-resistant HepG2 cells. These are in vitro findings and do not directly translate to human clinical effects.

In human studies, one exploratory trial assessed the effect of incorporating chickpeas into the ad libitum diet of 45 free-living adults, who consumed a minimum of 728 g of canned, drained chickpeas per week for 12 weeks, followed by 4 weeks of habitual diet without chickpeas. In the chickpea phase, mean dietary fiber intake was 6.77 g/day more and mean polyunsaturated fatty acid consumption was 2.66% higher, causing a favorable change in the polyunsaturated-to-saturated fatty acid ratio from 0.39 to 0.47. This study found that chickpeas may influence fatty acid and fiber intake in an ad libitum diet, leading to small improvements in serum lipid profile and glycemic control.

Evidence strength: The glycemic benefit of chickpea consumption is plausible given the food's low glycemic index and high fiber content. Multiple small randomized controlled trials (RCTs) and crossover trials suggest modest postprandial glucose-lowering effects, but the evidence as specifically pertaining to isolated chickpea protein (as distinct from whole chickpeas or chickpea flour) is largely preliminary and based on in vitro or animal mechanistic work, with limited high-quality human trials isolating the protein fraction itself.

4.2 Cardiovascular Health and Blood Lipids

Consumption of legumes has been shown to enhance health and lower the risk of cardiovascular disease. Researchers have focused on finding ACE inhibitors, antioxidant, and anti-inflammatory peptides from natural sources such as legumes, and in vitro and in vivo research has shown bioactive peptides generated from legume protein hydrolysates exhibit antioxidant, antihypertensive, anticancer, antiproliferative, and anti-inflammatory properties in the context of different disease mitigation.

Chickpea contains bioactive compounds with antidiabetic, antioxidant, antihypertensive, anti-inflammatory, and anticarcinogenic activity. In terms of ACE inhibition — the mechanism underlying pharmaceutical antihypertensive drugs — in silico and in vitro studies have highlighted that chickpea hydrolysates can inhibit ACE-I; however, chickpea peptides with ACE-I inhibitory potential are poorly characterized, and there is a lack of studies evaluating their effects in vivo or their molecular interactions with ACE-I in human subjects.

At the dietary level, plant-based proteins may have additional beneficial properties for human health when compared to animal protein sources, including reductions in risk factors for cardiovascular disease and contributions to increased satiety.

Evidence strength: The cardiovascular evidence for chickpea protein specifically is predominantly in vitro and computational (in silico). Human dietary trials have demonstrated favorable lipid and glycemic effects from whole chickpea consumption; however, isolating the protein fraction's contribution from those of fiber, resistant starch, and polyphenols has not been adequately accomplished in RCTs. The evidence is preliminary.

4.3 Protein Quality and Amino Acid Adequacy

Chickpea is a widely produced pulse crop that requires processing prior to human consumption. Protein bioavailability and amino acid quantity of chickpea flour can be altered by multiple factors, including the processing method. Processing differentially affects protein quality scores: extruded chickpea achieved a PDCAAS of 83.8, cooked chickpea 75.2, and baked chickpea 80.03; when assessed with the more modern DIAAS metric, baked chickpea scored 0.84, higher than both extruded (0.82) and cooked (0.78).

The in vitro protein digestibility of chickpea protein isolates ranges between 95.6% and 96.1%. Chickpea protein quality is considered equivalent to that of soybean meal.

Chickpea protein isolate (CPI) is a promising dietary protein with the advantages of low allergenicity, easy digestion, and a balanced composition of essential amino acids.

Evidence strength: The protein quality of chickpea has been thoroughly characterized through validated laboratory methods (PDCAAS, DIAAS, PER). DIAAS values below 1.0 reflect that chickpea is not a complete high-quality protein by those scoring standards when consumed alone, but its digestibility is high and, in the context of a varied diet complemented with cereals (which supply methionine), it provides a nutritionally adequate amino acid profile. This is established, reproducible compositional science.

4.4 Satiety and Body Weight Management

Human trials have examined chickpea's effects on satiety measures. One clinical trial reported that chickpea supplementation in an Australian diet affected food choice, satiety, and bowel health. The high protein and fiber content of chickpeas is mechanistically plausible for promoting satiety through multiple pathways. Chickpea protein's combination of protein and fiber promotes a feeling of fullness and satiety, supporting weight management by reducing overall calorie intake; the fiber content also aids in digestive health by promoting regular bowel movements and maintaining a healthy gut microbiome.

Evidence strength: Evidence for satiety effects is mostly indirect, derived from studies on whole pulse consumption or the known physiology of high-protein and high-fiber foods. Clinical trials specifically isolating chickpea protein as a supplement in controlled weight management studies are lacking. The existing evidence is consistent with legume consumption broadly rather than chickpea protein specifically.

4.5 Gut Microbiota

Animal research has demonstrated effects of chickpea consumption on gut health. The most active peptide fraction from germinated chickpea digest contained a total of 24 peptides derived from legumin and vicilin, and germinated chickpea protein concentrates showed potential to exert anti-inflammatory effects in the lower gut, which may contribute to the prevention of bowel inflammatory diseases. This was an animal study.

An active registered clinical trial (ClinicalTrials.gov NCT06914375) is investigating the effects of chickpea consumption on gut microbiome and metabolic health in a randomized, parallel-group intervention in 60 young adults over 8 weeks, reflecting that human microbiome evidence remains an open area of ongoing research.

Evidence strength: Gut microbiota effects of chickpea protein are largely preliminary, based on animal models and in vitro fermentation studies. No completed human RCTs isolating chickpea protein's effects on gut microbiota composition have been identified. The evidence is insufficient to draw firm conclusions.

4.6 Antioxidant Activity

Bioactive peptides from chickpea protein have been shown in cell-based studies to decrease levels of malondialdehyde (a marker of oxidative stress) and increase the levels of superoxide dismutase, glutathione, and glutathione peroxidase (endogenous antioxidant enzymes). These findings are from in vitro cell models.

Evidence strength: Antioxidant effects of chickpea protein-derived peptides are well-characterized in vitro. Whether these translate to measurable antioxidant effects in living humans after oral ingestion and digestion has not been established in adequately powered clinical trials. The evidence is preliminary and largely limited to laboratory conditions.

4.7 Anticancer Activity

Chickpea albumin hydrolysate formed by alcalase followed by Flavourzyme, fed to mice at 100 mg per kilogram of body weight per day, has significantly inhibited and reduced the number of tumors in mice; however, human studies are still required to establish whether chickpea protein hydrolysates and peptides exhibit anticarcinogenic effects.

Evidence strength: Anticancer activity is at an early, preclinical stage. There are no human clinical trials establishing anticancer efficacy of chickpea protein or its derived peptides. Claims of anticancer benefit in humans are not supported by current evidence.

5. Body Systems and Health Areas

• Metabolic / Endocrine System: Blood glucose modulation, insulin sensitivity improvement (in vitro and whole-food dietary studies); potential type 2 diabetes dietary management.
• Cardiovascular System: ACE inhibitory peptide activity (in vitro/in silico); modest serum lipid improvements in dietary trials using whole chickpeas; favorable polyunsaturated-to-saturated fat ratios.
• Gastrointestinal System: Bowel health, increased dietary fiber intake, gut microbiota modulation (animal and in vitro evidence); satiety signaling.
• Musculoskeletal System: Provision of dietary protein for muscle protein synthesis as part of an overall adequate protein intake; processed chickpea flour achieves PDCAAS scores of 75.2–83.8, indicating moderate-to-good protein quality sufficient for general population needs when complemented by other dietary proteins.
• Immune/Inflammatory System: Anti-inflammatory peptides derived from legumin and vicilin identified in vitro and in animal studies.
• Oxidative Stress: In vitro antioxidant activity of hydrolysates; elevated superoxide dismutase and glutathione in cell models.

6. Dosage Forms and Reported Dosages

Chickpea protein has not been standardized as a pharmaceutical or regulated supplement; dosages reported in studies reflect whole-food or ingredient use:

• In one human dietary study, participants consumed a minimum of 728 g of canned, drained chickpeas per week (the equivalent of four 300-g cans) as part of their habitual diet for 12 weeks.
• In an animal study using chickpea albumin hydrolysate, the dosage administered was 100 mg per kilogram of body weight per day.
• Chickpea protein isolate powders used in food technology research are characterized at protein concentrations of 78–88.1% on a dry weight basis, with typical serving sizes in food applications ranging from ~10–30 g of powder, though no specific human supplementation RCT has established an efficacious or optimal dose for any therapeutic endpoint.
• Commercial concentrates and isolates have been produced with protein contents reaching between 58% and 75%.
• In protein quality studies, chickpea flour processed by extrusion achieved a PDCAAS of 83.8 and baked chickpea achieved a DIAAS of 0.84.

No authoritative clinical body has established a recommended supplemental dose for isolated chickpea protein for any specific health indication.

7. Safety Considerations

7.1 Antinutritional Factors

Chickpeas may contain various antinutritional compounds, including protease inhibitors, phytic acid, lectins, oligosaccharides, and some phenolic compounds that may impair the utilization of nutrients.

Protease inhibitors, such as trypsin and chymotrypsin inhibitors, are particularly abundant in legumes including chickpeas. They hinder the activity of proteolytic enzymes in the gastrointestinal tract, thereby reducing protein digestibility. Chickpea is known to contain phytate and tannins, which bind with minerals like iron, zinc, and protein, decreasing their bioavailability and digestibility unless appropriate processing techniques are implemented; such antinutritional problems can be reduced by processing techniques such as dehulling, soaking, boiling, germinating, and roasting.

The antinutritional factors tannin and phytic acid in raw chickpeas can be reduced by 25–82.25% and 5.89–57.35%, respectively, through processing methods. All processing methods tested were effective in the reduction of antinutritional factors; however, boiling was found to be the best for their reduction.

Some varieties, such as Kabuli, contain low concentrations of antinutritional compounds like saponins, tannins, phytic acid, and trypsin inhibitors.

7.2 Allergenicity

Lentils and chickpeas are considered the most allergenic legumes in children living in Mediterranean and Asian countries. High consumption rates of chickpeas have enhanced allergic problems in sensitive individuals, as they contain many allergens.

Chickpea, alongside beans, peas, lentils, lupine, cowpea, pigeon pea, and fenugreek, is a potentially important allergen source causing mild-to-severe allergic reactions. Most legume allergens belong to the storage proteins family (with two superfamilies, cupins and prolamins), profilins, and pathogenesis-related proteins (PR-10).

Cross-reactivity between legumes depends on the presence of conserved epitopes accessible to antibodies, and it is typically described between allergens of the same protein family. Individuals with known allergies to other legumes — including peanuts, soy, or lentils — may be at risk for cross-reactive responses to chickpea protein preparations.

7.3 Gastrointestinal Tolerability

Chickpea contains anti-nutritional compounds including lectins, phenolic compounds, trypsin inhibitors, inositol phosphates, saponins, oxalic acid, and flatulence-causing soluble carbohydrates such as α-galacto-oligosaccharides. These compounds, if ingested in large quantities, could act as anti-nutritional factors and represent a limiting factor for chickpea use in human nutrition. Gastrointestinal discomfort, bloating, and flatulence associated with oligosaccharides (raffinose, stachyose) are known tolerability issues with raw or inadequately processed chickpea. Adequate cooking substantially mitigates these effects.

7.4 Interactions with Drug Metabolism

No established pharmacokinetic drug interactions have been documented for chickpea protein in human clinical literature. The phytic acid content may theoretically reduce the absorption of co-ingested minerals (iron, zinc, calcium) and some medications that depend on mineral cofactors; however, specific drug interaction data in humans are absent from the peer-reviewed literature reviewed.

7.5 Processing and Protein Quality Trade-Offs

Protein bioavailability and amino acid quantity of chickpea flour can be altered by multiple factors, including the processing method. Over-processing (e.g., high-temperature extrusion or roasting) can reduce the availability of lysine through Maillard reactions, while some processing methods simultaneously reduce antinutritional factors and improve digestibility. The net effect on protein quality depends on the specific conditions used.

References

• Pascual-Bustamante S et al. (2024). Chemical and Protein Characterization of Two Varieties of Chickpea (Cicer arietinum): Costa 2004 and El Patrón. Plants, 13(15), 2125. PMC
• Xinjiang Kabuli and Desi Chickpea Chemical Composition Study. PMC (2023).
• Frontiers in Nutrition (2023). Nutritional composition, health benefits and bio-active compounds of chickpea (Cicer arietinum L.).
• Sanchez-Vioque R et al. (1999). Protein isolates from chickpea (Cicer arietinum L.): chemical composition, functional properties and protein characterization. Food Chemistry.
• Mass Spectrometry Characterization of the SDS-PAGE Protein Profile of Legumins and Vicilins from Chickpea Seed. PMC (2024).
• Mass Spectrometry Characterization of Legumins and Vicilins from Chickpea Seed. Foods (2024). MDPI.
• Understanding the structural differences in chickpea globulins and their relationship with in vitro protein digestibility. Food Research International (2025). ScienceDirect.
• Pittaway JK et al. (2008). Chickpeas may influence fatty acid and fiber intake in an ad libitum diet, leading to small improvements in serum lipid profile and glycemic control. Journal of the American Dietetic Association. PubMed.
• Effectiveness of Chickpeas on Blood Sugar: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PMC (2023).
• Identification and Function Analysis of Novel Hypoglycemic and Antioxidant Peptides from Chickpea. Plant Foods for Human Nutrition (2024). Springer.
• Arámburo-Gálvez JG et al. (2022). Prediction of ACE-I Inhibitory Peptides Derived from Chickpea (Cicer arietinum L.): In Silico Assessments. Foods. PMC.
• Recent Advances in In Vitro and In Vivo Studies of Antioxidant, ACE-Inhibitory and Anti-Inflammatory Peptides from Legume Protein Hydrolysates. PubMed (2023).
• Thermal processing methods differentially affect the protein quality of Chickpea (Cicer arietinum). PMC (2020).
• Plant Proteins: Methods of Quality Assessment and the Human Health Benefits of Pulses. PMC (2023).
• IgE-Mediated Legume Allergy: A Pediatric Perspective. PMC (2024).
• Health Risks and Benefits of Chickpea (Cicer arietinum) Consumption. Journal of Agricultural and Food Chemistry (2016). ACS Publications.
• Legume Allergens Pea, Chickpea, Lentil, Lupine and Beyond. Current Allergy and Asthma Reports (2024). Springer.
• Physicochemical Properties and Effect of Processing Methods on Mineral Composition and Antinutritional Factors of Improved Chickpea Varieties. PMC (2019).
• Sowing Date and Seeding Rate Affect Bioactive Compound Contents of Chickpea Grains. PMC (2019).
• Enhancement of Extraction Efficiency and Functional Properties of Chickpea Protein Isolate Using Pulsed Electric Field Combined with Ultrasound Treatment. PMC (2024).
• Chickpea Processing to Obtain a Protein Ingredient for the Plant-Based Market. Frontiers in Food Science and Technology (2025).
• Wikipedia: Chickpea (for historical/cultural overview, cross-referenced with primary sources).
• McGrath C (2023). Genetic Signatures of Chickpea's Cultural Crossroads. Molecular Biology and Evolution. PMC.
• Digestible Indispensable Amino Acid Score (DIAAS): 10 Years On. PMC (2024).
• Impact of Resistant Starch Formation in Chickpea Products on Blood Glucose and Lipid Profiles. ScienceDirect (2025).
• Enzymatic Treatment Improves ACE-I Inhibition and Antiproliferative Potential of Chickpea. Vegetos (2019). Springer.
• Chickpea-supplemented diet alters the gut microbiome and enhances gut barrier integrity in C57Bl/6 male mice. Journal of Functional Foods (2017). ScienceDirect.
• Research Progress of Food-Derived Antihypertensive Peptides in Regulating the Renin–Angiotensin System. PMC (2025).